Evaluation of efficacy of yokukansan in patients with dementia with Lewy bodies using NPI-D as an indicator. - Examination of efficacy of yokukansan in patients with dementia with Lewy bodies

Department of Geriatric Medicine, Kyorin University School of Medicine0 个研究点目标入组 20 人开始时间: 2009年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with malignancy, severe disease of heart, liver, renal, blood, lung and other life-threatening diseases 2) Patients who fail to meet the DSM-IV diagnostic criteria for our study, but show symptoms of BPSD due to other concomitant neurodegenerative disease, schizophrenia, bipolar disorder, major depression or other psychiatric disorders 3) Patients with delirium due to alcohol or drug addictions, metabolic poisoning, or inflammatory disease 4) Patients who are unable to take oral medications 5) Patients initiated the therapy with donepezil hydrochloride or made change in dosage and administration of the drug within 8 weeks before the start of treatment 6) Patients received drugs prohibited for concomitant use or drugs restricted in concomitant use during wash-out period, 7) Patients who took long acting antipsychotic drugs (such as haloperidol decanoate) within 4 weeks before the start of treatment 8) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above

发起方

Department of Geriatric Medicine, Kyorin University School of Medicine